Clinical Trials Logo
  1. Home
  2. Major Depressive Disorder (MDD)
  3. NCT06044818
  4. Details
NCT06044818 Clinical Trial

Validation of Accexible as a Tool for Screening and Monitoring Depression.

Major Depressive Disorder (MDD) Clinical Trial

Official title:
Validación Del Sistema de Cribaje y Seguimiento de acceXible Para depresión.

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06044818
Other study ID # PR(AG)86/2023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 22, 2024
Est. completion date January 3, 2025

Study information
Verified date January 2024
Source Accexible
Contact Carla Zaldua
Phone +34 649 33 22 95
Email carla@accexible.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating Accexible as a tool for Screening and Monitoring Depression.

Recruitment information / eligibility
Status Recruiting
Enrollment 178
Est. completion date January 3, 2025
Est. primary completion date October 3, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Adult 18-65 years of age. - Participants must have Spanish as their first language (able to speak and understand verbal messages). - Participants must have mobile phone with internet. - Participants must have the ability to understand AcceXible's basic instructions. - Participants must agree to participate in the study and have voluntarily signed the informed consent. Exclusion Criteria for patients: - To have received a diagnosis of neurodegeneration. - To have significant vision problems that would affect the ability to perceive visual stimuli. - To have significant hearing problems that would affect the ability to understand verbal cues. - To be unable to give informed consent to participate in the study.

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Accexible
Speech Analysis

Locations
Country Name City State
Spain Vall d'Hebron Institut de Investigación (VHIR) Barcelona

Sponsors (1)
Lead Sponsor Collaborator
Accexible

Country where clinical trial is conducted

Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Prevalence of Depression questionnaire An average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT05416957 - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Phase 1
Active, not recruiting NCT03642964 - A Study in Patients With Major Depressive Disorder Phase 2
Terminated NCT01111565 - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT01912196 - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT00958204 - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression Phase 3
Completed NCT00102492 - Study Of GW679769 In Major Depressive Disorder Phase 2
Completed NCT02012218 - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Phase 3
Completed NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Phase 4
Completed NCT00768430 - Optimization of IV Ketamine for Treatment Resistant Depression Phase 2
Completed NCT00559299 - Patient Tolerability Study of GSK163090 Phase 1
Terminated NCT01123707 - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT04403373 - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study N/A
Completed NCT05541302 - Retrospective TMS Therapy for Adults With MDD
Not yet recruiting NCT06385405 - Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment N/A
Completed NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan Phase 2
Recruiting NCT03012724 - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) N/A
Completed NCT02380066 - Comparison of Anyu Peibo With Placebo in Treatment of MDD Phase 2
Not yet recruiting NCT02395263 - Comparison of Yuxintine With Placebo in Treatment of MDD Phase 2
Completed NCT01187407 - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Phase 3